Ataxia Telangiectasia (AT) is a rare multisystem disorder caused by pathogenic variants in the ATM gene and mainly characterized by progressive neurodegeneration, immunodeficiency, increased susceptibility to malignancy and evidence of chronic inflammation. Although different molecular mechanisms underlying AT pathogenesis and its major clinical manifestations have been characterized, the crosstalk among immune dysfunction, inflammatory signaling and neurodegeneration remains difficult to investigate experimentally. Particularly in the context of a rare disease, computational approaches may help integrate diverse biological processes into a coherent systems-level representation. Here, we present UISS-AT, a mechanistic agent-based model of AT developed within the Universal Immune System Simulator (UISS) framework. The model was designed to reproduce core features of AT pathophysiology, including thymic hypoplasia, T-cell deficiency, B-cell defects, impaired V(D)J recombination, class-switch recombination failure, chronic cytokine dysregulation, immunosenescence, susceptibility to infection and progressive Purkinje-cell loss as a neurological endpoint. Simulations were performed on a virtual cohort of 100 AT patients and analyzed at the cohort level over a 10-year time horizon. UISS-AT reproduced the key hallmarks of AT natural history, comprising progressive lymphopenia, humoral immunodeficiency, sustained increases in TNF-α, IL-6 and IL-8 and progressive Purkinje cell degeneration. A treatment layer describing the pharmacodynamic effects of betamethasone and dexamethasone was then implemented, and five clinically informed regimens were evaluated. The model reproduced transient reductions in inflammatory cytokines, partial stabilization of lymphocyte trajectories and temporary slowing of Purkinje-cell loss, consistent with the short-term therapeutic effects reported in AT clinical studies. Together, these results support the biological plausibility of UISS-AT as a mechanistically grounded in silico platform for studying AT disease progression and therapeutic modulation. UISS-AT provides a foundation for future virtual-cohort analyses, comparative evaluation of treatment strategies and model-informed rare-disease research.